ClinicalTrials.gov
Cure8 trial brief
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Research and clinical trials
Infliximab
Anti-TNF
Phase 2 clinical trial
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
This registry will collect one-year, patient-reported outcomes on symptom control and clinical remission while people with IBD receive Zymfentra (infliximab-dyyb) in routine care — information that may help patients and clinicians understand real-world effectiveness of this infliximab biosimilar.
Who Should Pay Attention
Adult patients with Crohn's disease or ulcerative colitis, patients on biologics, clinicians prescribing infliximab/biosimilars, and IBD researchers.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment200 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is an observational (non-interventional) registry that aims to enroll about 200 participants who are prescribed Zymfentra during regular clinical care. Participants complete online surveys using the SCCAI and other timepoints up to 52 weeks; the study will describe symptom trajectories and remission rates as reported by patients.
The study is recruiting at multiple U.S. academic centers. Because it is observational, it tracks outcomes under usual-care conditions rather than assigning or randomizing treatments; it can provide useful real-world data but cannot prove causation or compare Zymfentra to other therapies in a randomized way.
Keep In Mind
This is an observational, non-randomized registry (recruiting) and will describe patient-reported outcomes over time; it does not establish causal efficacy compared with other treatments. The study record is a trial registration (ClinicalTrials.gov) describing planned data collection, not published trial results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of North Carolina, Chapel Hill
Trial IDNCT07237516
Study typeObservational
Enrollment200 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 31, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...